Histogenics Misses Mark To Raise $65M In IPO
Massachusetts-based Histogenics Corp., which is developing a regenerative tissue treatment for damaged knee cartilage, priced significantly below its targeted price range to raise $65 million before listing on the Nasdaq on...To view the full article, register now.
Already a subscriber? Click here to view full article